Owners, management and financials
CVR: 26527767
Secondary names: LIFECYCLE PHARMA A/S
Not available
Asahi Kasei Corporation (100%)
CVR · view owners
Daisuke Matsuo
Board: Keigo Nakatsukasa (chair) and 2 members
CVR · view management
Active
Founded 21 March 2002
CVR · view overview
2 employees
CVR · 2018
Director registered: Daisuke Matsuo
CVR · 09/10/2024
View the full event history
VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 2 employees (2018). Equity in the 2025 report amounted to USD 88,648,000.
Selskabets formål er at udøve medicinsk forskning, produktion og salg af sådanne produktet samt anden dermed i forbindelse stående virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/04/2024 – 31/03/2025 | - | - | 89.9 mio. USD | 88.6 mio. USD | 1 | |
| 202401/04/2023 – 31/03/2024 | - | - | 3.3 mio. USD | -10.5 mio. USD | 1 | |
| 202301/04/2022 – 31/03/2023 | - | - | 3.4 mio. USD | 2.8 mio. USD | 1 | |
| 202201/04/2021 – 31/03/2022 | 0 USD | 2.1 mio. USD | 3.9 mio. USD | 2.9 mio. USD | - | |
| 202101/04/2020 – 31/03/2021 | 45.3 mio. USD | 1.1 mia. USD | 1.3 mia. USD | 1.3 mia. USD | - | |
| 201801/01/2018 – 31/12/2018 | 39.5 mio. USD | -5.3 mio. USD | 77.1 mio. USD | 4.6 mio. USD | - | |
| 201701/01/2017 – 31/12/2017 | 30.2 mio. USD | -9.5 mio. USD | 41.9 mio. USD | 5.3 mio. USD | - | |
| 201601/01/2016 – 31/12/2016 | 9.2 mio. USD | -10.1 mio. USD | 29.9 mio. USD | 10.2 mio. USD | - | |
| 201501/01/2015 – 31/12/2015 | 14.2 mio. | -176.1 mio. | 149 mio. | 89.7 mio. | - | |
| 201401/01/2014 – 31/12/2014 | 123.4 mio. | -36.3 mio. | 293.7 mio. | 253.2 mio. | - |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of VELOXIS PHARMACEUTICALS A/S is 26527767.
VELOXIS PHARMACEUTICALS A/S is owned by Asahi Kasei Corporation.
The management of VELOXIS PHARMACEUTICALS A/S consists of Daisuke Matsuo.
The board of VELOXIS PHARMACEUTICALS A/S consists of Keigo Nakatsukasa, Daisuke Matsuo and Kenro Yuzaki, with Keigo Nakatsukasa as chair.
VELOXIS PHARMACEUTICALS A/S had 2 employees in 2018 according to the Danish CVR register.
VELOXIS PHARMACEUTICALS A/S was founded on 21 March 2002.
Claim this page to add your logo and social links. Free to get started.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2025.
As of September 4, 2025, Kenro Yuzaki has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of September 4, 2025, Yusuke Hiramatsu has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2024.
As of October 9, 2024, Daisuke Matsuo is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of October 8, 2024, Mark Earl Hensley has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2023.
As of May 22, 2023, Keigo Nakatsukasa has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of May 22, 2023, Hideo Hikami has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK 2,060,000.
As of August 31, 2022, Yusuke Hiramatsu has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of August 31, 2022, Hiroki Ideguchi has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of November 8, 2021, Mark Earl Hensley is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of November 8, 2021, Craig Alexander Collard has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of November 8, 2021, Ira Duarte has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2021. Revenue came to DKK 45,335,000, and the net result was DKK 1,057,461,000.
As of April 14, 2021, Hideo Hikami has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 14, 2021, Hiroki Ideguchi has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 14, 2021, Masaya Etoh has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 14, 2021, Matthew Ryan Dumont has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of January 4, 2021, is registered as an owner of VELOXIS PHARMACEUTICALS A/S with an ownership share of 100%.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2019 – March 31, 2020.
As of March 10, 2020, Masaya Etoh has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of March 9, 2020, Masaya Etoh has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Masaya Etoh has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Matthew Ryan Dumont has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Daisuke Matsuo has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Mette Kirstine Agger has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Anders Götzsche has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Lars Kåre Viksmoen has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Michael Thomas Heffernan has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Paul Kevin Wotton has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 17, 2020, Robert Samuel Radie has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2019 – September 30, 2019.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2019 – June 30, 2019.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2019 – March 31, 2019.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2018. Revenue came to DKK 39,494,000, and the net result was DKK -5,285,000.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2018 – September 30, 2018.
As of October 31, 2018, Ira Duarte is registered as director of VELOXIS PHARMACEUTICALS A/S.
As of September 24, 2018, Morten Marott has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2018 – June 30, 2018.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2018 – March 31, 2018.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2017. Revenue came to DKK 30,167,000, and the net result was DKK -9,542,000.
As of April 3, 2018, Morten Marott is registered as director of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2017 – September 30, 2017.
As of September 20, 2017, Alastair Stuart McEwan has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2017 – June 30, 2017.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2017 – March 31, 2017.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2016. Revenue came to DKK 9,194,000, and the net result was DKK -10,135,000.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2016 – June 30, 2016.
As of July 26, 2016, Lars Kåre Viksmoen has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of July 26, 2016, Paul Kevin Wotton has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of July 26, 2016, Robert Samuel Radie has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of July 26, 2016, Thomas Peter Dyrberg has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2016 – March 31, 2016.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2015. Revenue came to DKK 14,150,000, and the net result was DKK -176,106,000.
As of April 7, 2016, Johnny Stilou has stepped down as økonomidirektør of VELOXIS PHARMACEUTICALS A/S.
As of April 6, 2016, Mette Kirstine Agger has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 6, 2016, Thomas Peter Dyrberg has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 6, 2016, Michael Thomas Heffernan has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 5, 2016, Mette Kirstine Agger has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 5, 2016, Thomas Peter Dyrberg has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 5, 2016, Michael Thomas Heffernan has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of February 29, 2016, Alastair Stuart McEwan is registered as director of VELOXIS PHARMACEUTICALS A/S.
As of December 10, 2015, Craig Alexander Collard is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of December 10, 2015, William James Polvino has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2015 – September 30, 2015.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2015 – June 30, 2015.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2015 – March 31, 2015.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2014. Revenue came to DKK 123,395,000, and the net result was DKK -36,319,000.
As of March 26, 2015, Mette Kirstine Agger has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of March 26, 2015, Michael Thomas Heffernan has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of March 26, 2015, Kim Bjørnstrup has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of March 25, 2015, Mette Kirstine Agger has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period July 1, 2014 – September 30, 2014.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2014 – March 31, 2014.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2014 – June 30, 2014.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2013.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2013 – June 30, 2013.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2013 – March 31, 2013.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2012.
As of April 17, 2013, Kurt Anker Nielsen has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 17, 2013, Edward Etienne Penhoet has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of May 23, 2012, Johnny Stilou is registered as økonomidirektør of VELOXIS PHARMACEUTICALS A/S.
As of May 23, 2012, Peter Gudmund Nielsen has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
As of July 7, 2011, Edward Etienne Penhoet has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of VELOXIS PHARMACEUTICALS A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of VELOXIS PHARMACEUTICALS A/S.
As of April 12, 2011, Kim Bjørnstrup has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 12, 2011, Jean Joachim Deleage has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 12, 2011, Gaston Georges Gerard Soula has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 12, 2011, Paul Edick has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 21, 2010, Mette Kirstine Agger has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of December 2, 2009, William James Polvino is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of August 31, 2009, Thomas Peter Dyrberg has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of August 31, 2009, James Stewart New has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of April 23, 2009, Paul Edick has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 23, 2009, Claus Tycho Bræstrup has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 16, 2009, Karin Jexner Hamberg has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
As of December 1, 2008, Hans Christian Eberhard Groth Teisen has stepped down as økonomidirektør of VELOXIS PHARMACEUTICALS A/S.
As of December 1, 2008, Michael Beckert has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
As of October 21, 2008, James Stewart New is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of September 22, 2008, Karin Jexner Hamberg is registered as director of VELOXIS PHARMACEUTICALS A/S.
As of July 31, 2008, Flemming Ørnskov has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of April 24, 2008, Anders Götzsche has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 24, 2008, Peter Gudmund Nielsen is registered as director of VELOXIS PHARMACEUTICALS A/S.
As of April 24, 2008, Michael Beckert is registered as director of VELOXIS PHARMACEUTICALS A/S.
As of February 29, 2008, Hans Christian Eberhard Groth Teisen is registered as økonomidirektør of VELOXIS PHARMACEUTICALS A/S.
As of February 29, 2008, Michael Wolff Jensen has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
As of September 7, 2006, Kurt Anker Nielsen has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of September 7, 2006, Claus Tycho Bræstrup has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of September 7, 2006, Flemming Ørnskov has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of September 7, 2006, Flemming Ørnskov is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of September 7, 2006, Jan Møller Mikkelsen has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of March 7, 2006, Anders Buur has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of December 16, 2005, Florian Schønharting has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of November 7, 2005, Gaston Georges Gerard Soula has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of September 21, 2005, Flemming Ørnskov has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 30, 2005, A/S PSE NR. 4820 has been appointed auditor of VELOXIS PHARMACEUTICALS A/S.
As of June 30, 2005, Pricewaterhouse Coopers has stepped down as auditor of VELOXIS PHARMACEUTICALS A/S.
As of June 20, 2005, Jean Joachim Deleage has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 20, 2005, Ole Vahlgren has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of November 3, 2003, Pricewaterhouse Coopers has been appointed auditor of VELOXIS PHARMACEUTICALS A/S.
As of November 3, 2003, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of VELOXIS PHARMACEUTICALS A/S.
As of October 31, 2003, Tomas Norling has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
As of August 1, 2003, Michael Wolff Jensen is registered as director of VELOXIS PHARMACEUTICALS A/S.
As of January 1, 2003, Jan Møller Mikkelsen is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Florian Schønharting has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Ole Vahlgren has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Anders Buur has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Klaus Søgaard has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Jan-Erik Gunnar Svensson has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Troels Elkiær Andersen has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Tomas Norling is registered as director of VELOXIS PHARMACEUTICALS A/S.
As of June 6, 2002, Klaus Søgaard has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
As of March 21, 2002, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of VELOXIS PHARMACEUTICALS A/S.
As of March 21, 2002, Klaus Søgaard has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of March 21, 2002, Jan-Erik Gunnar Svensson has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of March 21, 2002, Troels Elkiær Andersen has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of March 21, 2002, Klaus Søgaard is registered as director of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S was founded on March 21, 2002.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Companies in the same industry and area
CVR 29418888
CVR 29769796
CVR 34688605
CVR 34892970
CVR 35047565
